Trial Profile
The effect of Carboplatin and Bevacizumab on progression free survival in recurrent Glioblastoma Multiforme: A randomised phase II study.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Mar 2019
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Etoposide; Temozolomide
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms CABARET
- 05 Jul 2017 Results published in the Cancer
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2015 Status changed from active, no longer recruiting to completed, according to results presented at ASCO 2015.